MedTrace Logo

Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects

NCT06607744 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2026-02-25

No results posted yet for this study

Summary

The goal of this clinical study is to obtain the bioavailability of the test patch of a generic formulation of Selegiline TDS 6mg/24 hours by Corium Innovations against the comparator (EMSAM), and the systemic and local safety and tolerability will be also observed and evaluated.

Conditions

Interventions

DRUG

Pharmacokinetic profiles of Selegiline TDS and EMSAM

Selegiline concentrations will be measured in blood plasma using a validated liquid chromatography tandem mass spectrometry method from Selegiline TDS (test formulation 6mg/24 hours) and EMSAM (6mg/24 hours). The analytical laboratory will be blinded as to samples which are the test and reference products.

Sponsors & Collaborators

  • Corium Innovations, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-10
Primary Completion
2025-03-25
Completion
2025-03-25
FDA Drug
Yes

Countries

  • Malaysia

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06607744 on ClinicalTrials.gov